These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8497383)

  • 1. A double-blind randomized crossover study to compare the antiemetic efficacy of 250 mg with 500 mg methylprednisolone succinate (Solu-Medrol) as a single intravenous dose in patients treated with noncisplatin chemotherapy.
    Pieters RC; Vermorken JB; Gall HE; Nauta JJ; van Loenen AC; van Groeningen CJ; van Rijswijk RE; Brenninkmeijer JH; Pinedo HM
    Oncology; 1993; 50(4):316-22. PubMed ID: 8497383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
    Gralla RJ; Navari RM; Hesketh PJ; Popovic W; Strupp J; Noy J; Einhorn L; Ettinger D; Bushnell W; Friedman C
    J Clin Oncol; 1998 Apr; 16(4):1568-73. PubMed ID: 9552067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High doses of methylprednisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study.
    Giaccone G; Bertetto O; Secat MA; Calciati A
    Oncology; 1988; 45(2):74-8. PubMed ID: 3353076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
    Coiffier B; Khayat D; Misset JL; Votan B
    Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial.
    Kobashigawa JA; Stevenson LW; Moriguchi JD; Kawata N; Brownfield E; Drinkwater DC; Laks H
    J Am Coll Cardiol; 1993 Apr; 21(5):1142-4. PubMed ID: 8459068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial.
    Go SI; Koo DH; Kim ST; Song HN; Kim RB; Jang JS; Oh SY; Lee KH; Lee SI; Kim SG; Park LC; Lee SC; Park BB; Ji JH; Yi SY; Lee YG; Yun J; Bruera E; Hwang IG; Kang JH
    Oncologist; 2017 Nov; 22(11):1354-1361. PubMed ID: 28687626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative study of the effect of granisetron and a combination of granisetron plus steroids on cancer chemotherapy induced emesis].
    Nukariya N; Nakarai I; Kobayashi H; Koizumi W; Komatsu H; Uchiyama T; Yamaguchi T; Taira O; Minato K; Futatsugi K
    Gan To Kagaku Ryoho; 1995 Oct; 22(12):1821-9. PubMed ID: 7574816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylprednisolone as an intervention following myocardial infarction. The Solu-Medrol Sterile Powder AMI Studies Group.
    J Int Med Res; 1986; 14 Suppl 1():1-10. PubMed ID: 2875003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide.
    Aapro MS; Plezia PM; Alberts DS; Graham V; Jones SE; Surwit EA; Moon TE
    J Clin Oncol; 1984 May; 2(5):466-71. PubMed ID: 6539363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiemetic treatment with two different doses of methylprednisolone in breast cancer patients: a double-blind randomized cross-over study with evaluation of efficacy parameters.
    Havsteen H; Kjaer M
    Anticancer Drugs; 1996 Jul; 7(5):535-42. PubMed ID: 8862721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Side effects during treatment with Solu-Medrol for optic neuritis in the course of MS].
    Mazur-Chłodek L; Kaliciak-Kempińska A
    Klin Oczna; 2003; 105(3-4):194-6. PubMed ID: 14552184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.
    Strum SB; McDermed JE; Liponi DF
    J Clin Oncol; 1985 Feb; 3(2):245-51. PubMed ID: 4038511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOLU-MEDROL (methylprednisolone sodium succinate, USP).
    Sjogren E
    Crit Care Nurse; 1983; 3(5):26-8. PubMed ID: 6354596
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
    Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF
    Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.